Today begins Cowboys off-season workout program – which is voluntary. The fact Dez Bryant hasn’t yet signed his franchise-tag contract justifies his absence. But Orlando Scandrick isn’t there, either and both players are visiting with The Fan about what’s going on.
First place in the NFC East is on the line when the Eagles (9-4) host the Cowboys (9-4) under the prime-time lights Sunday night.
The Dallas Cowboys are in a must-win situation if they want to make the playoffs and really showed how great their offense is with a huge win over the Chicago Bears on the road. Here is a look at the Cowboys team grades.
Dallas Cowboys cornerback Orlando Scandrick joins the Ben and Skin show to discuss the Cowboys season so far and the perception that he is aloof when it comes to dealing with the media.
Mo Claiborne returned to Valley Ranch on Wednesday a day after a noon-time departure from the Cowboys’ facility while reacting angrily to his demotion from the starting lineup.
Dallas Cowboys cornerback Mo Claiborne will be punished by the team but will play this week after leaving team facilities and missing practice on Tuesday.
Cowboys cornerback Mo Claiborne left the team’s training facility Tuesday after learning that he will be replaced in the starting lineup, 105.3 The Fan confirms.
After two seasons of lackluster play, Morris Claiborne is now in danger of losing his starting job as the Dallas Cowboys’ cornerback.
While Jerry Jones admits that Claiborne hasn’t lived up to expectations, he’s adamant that the Cowboys corner has a future within the team’s defensive scheme.
Orlando Scandrick was “thankful” and “relieved” when his four-game suspension was cut short by a revised drug policy. But after his return game, the tone had changed.
Scandrick arrived at at the club’s Valley Ranch headquarters this morning and rejoined the team as the result of the NFL reaching an agreement with the NFL Players Association on changes to its performance-enhancing drug policy.
The NFL says it has reached an agreement with the players association on changes to its performance-enhancing drug policy, including the addition of human growth hormone testing.